132 related articles for article (PubMed ID: 32878569)
21. A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer.
An JY; Choi YY; Lee J; Hyung WJ; Kim KM; Noh SH; Choi MG; Cheong JH
Cancer Res Treat; 2020 Oct; 52(4):1153-1161. PubMed ID: 32599987
[TBL] [Abstract][Full Text] [Related]
22. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China.
Huang J; Mo H; Zhang W; Chen X; Qu D; Wang X; Wu D; Wang X; Lan B; Yang B; Wang P; Zhang B; Yang Q; Jiao Y; Xu B
Cancer; 2019 Mar; 125(5):742-749. PubMed ID: 30508306
[TBL] [Abstract][Full Text] [Related]
23. Mixed adenoneuroendocrine carcinoma (MANEC) of the gastroesophageal junction: a case report and review of the literature.
Juanmartiñena JF; Fernández-Urién I; Córdoba A; Miranda C; Borda A
Rev Esp Enferm Dig; 2017 Feb; 109(2):160-162. PubMed ID: 26999428
[TBL] [Abstract][Full Text] [Related]
24. [Mixed adenoneuroendocrine carcinoma (MANEC) of the gastrointestinal tract].
Šefr R; Němec L; Fabian P; Fiala L
Rozhl Chir; 2017; 96(1):41-44. PubMed ID: 28325058
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer.
Kasi PM; Budde G; Krainock M; Aushev VN; Koyen Malashevich A; Malhotra M; Olshan P; Billings PR; Aleshin A
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101943
[TBL] [Abstract][Full Text] [Related]
27. PD-1 Blockade in Advanced Adrenocortical Carcinoma.
Raj N; Zheng Y; Kelly V; Katz SS; Chou J; Do RKG; Capanu M; Zamarin D; Saltz LB; Ariyan CE; Untch BR; O'Reilly EM; Gopalan A; Berger MF; Olino K; Segal NH; Reidy-Lagunes DL
J Clin Oncol; 2020 Jan; 38(1):71-80. PubMed ID: 31644329
[TBL] [Abstract][Full Text] [Related]
28. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
[TBL] [Abstract][Full Text] [Related]
29. Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report.
Semrau S; Agaimy A; Pavel M; Lubgan D; Schmidt D; Cavallaro A; Golcher H; Grützmann R; Fietkau R
J Med Case Rep; 2019 Mar; 13(1):82. PubMed ID: 30902067
[TBL] [Abstract][Full Text] [Related]
30. PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix.
Morgan S; Slodkowska E; Parra-Herran C; Mirkovic J
Histopathology; 2019 Jun; 74(7):997-1004. PubMed ID: 30667073
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Fuchs CS; Doi T; Jang RW; Muro K; Satoh T; Machado M; Sun W; Jalal SI; Shah MA; Metges JP; Garrido M; Golan T; Mandala M; Wainberg ZA; Catenacci DV; Ohtsu A; Shitara K; Geva R; Bleeker J; Ko AH; Ku G; Philip P; Enzinger PC; Bang YJ; Levitan D; Wang J; Rosales M; Dalal RP; Yoon HH
JAMA Oncol; 2018 May; 4(5):e180013. PubMed ID: 29543932
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas.
Koh J; Nam SK; Kwak Y; Kim G; Kim KK; Lee BC; Ahn SH; Park DJ; Kim HH; Park KU; Kim WH; Lee HS
J Pathol; 2021 Jan; 253(1):94-105. PubMed ID: 32985687
[TBL] [Abstract][Full Text] [Related]
33. Neuroendocrine liver metastasis in gastric mixed adenoneuroendocrine carcinoma with trilineage cell differentiation: a case report.
Zhang W; Xiao W; Ma H; Sun M; Chen H; Zheng S
Int J Clin Exp Pathol; 2014; 7(9):6333-8. PubMed ID: 25337287
[TBL] [Abstract][Full Text] [Related]
34. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
35. Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.
Fernández A
Trends Cancer; 2017 Oct; 3(10):675-677. PubMed ID: 28958385
[TBL] [Abstract][Full Text] [Related]
36. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
37. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
[TBL] [Abstract][Full Text] [Related]
38. Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system.
Hirsch D; Gaiser T; Merx K; Weingaertner S; Forster M; Hendricks A; Woenckhaus M; Schubert T; Hofheinz RD; Gencer D
J Cancer Res Clin Oncol; 2021 Jan; 147(1):263-273. PubMed ID: 32776177
[TBL] [Abstract][Full Text] [Related]
39. Deep and Durable Response With Combination CTLA-4 and PD-1 Blockade in Mismatch Repair (MMR)-proficient Endometrial Cancer.
Oh MS; Chae YK
J Immunother; 2019; 42(2):51-54. PubMed ID: 30247204
[TBL] [Abstract][Full Text] [Related]
40. PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment.
Chen JA; Esteghamat N; Kim EJ; Garcia G; Gong J; Fakih MG; Bold RJ; Cho MT
J Natl Compr Canc Netw; 2019 Sep; 17(9):1026-1030. PubMed ID: 31487676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
